Back to Search
Start Over
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
- Source :
- Contemporary Clinical Trials Communications; August 2022, Vol. 28 Issue: 1
- Publication Year :
- 2022
-
Abstract
- Approximately 60% of patients with chronic constipation (CC) have a significantly higher rate of loss of defecation desire (LODD). Bile acids are expected to have a restorative effect on defecation desire (DD) because they lower the rectal sensory threshold, which is an objective index of DD. Elobixibat (EXB) specifically inhibits the ileal bile acid transporter/apical sodium-dependent bile acid transporter, which is a transporter involved in the reabsorption of bile acids in the terminal ileum. This study aims to investigate the LODD improvement rate in patients with CC after 4 weeks of EXB treatment.
Details
- Language :
- English
- ISSN :
- 24518654
- Volume :
- 28
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Contemporary Clinical Trials Communications
- Publication Type :
- Periodical
- Accession number :
- ejs61955621
- Full Text :
- https://doi.org/10.1016/j.conctc.2022.100958